Inhibrx Biosciences (INBX) Projected to Post Earnings on Tuesday

Key Points

• Inhibrx Biosciences (NASDAQ:INBX) is set to release its Q2 2025 earnings on August 12th, with a projected loss of ($2.92) per share, following a previous loss of ($2.80) that missed analyst expectations.
• The company's market capitalization stands at $314.65 million with a stock price of $21.73, having a significant debt-to-equity ratio of 1.04 and a P/E ratio of 0.19.
• Institutional investors dominate the ownership with 82.46% of the company's shares held by institutions, including a new stake acquired by Strs Ohio.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($2.92) per share for the quarter.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by ($0.25). On average, analysts expect Inhibrx Biosciences to post $105 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Inhibrx Biosciences Trading Down 1.3%

Shares of Inhibrx Biosciences stock traded down $0.28 during mid-day trading on Friday, hitting $21.06. The stock had a trading volume of 80,424 shares, compared to its average volume of 108,785. The firm has a 50-day moving average of $18.41 and a two-hundred day moving average of $14.75. Inhibrx Biosciences has a 12-month low of $10.80 and a 12-month high of $25.29. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 1.04. The firm has a market cap of $304.95 million, a P/E ratio of 0.18 and a beta of 0.24.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inhibrx Biosciences stock. Strs Ohio bought a new stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,900 shares of the company's stock, valued at approximately $27,000. Hedge funds and other institutional investors own 82.46% of the company's stock.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx Biosciences in a report on Thursday, May 15th.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.